Fragile X syndrome (FXS) is the most common form of inherited intellectual disability (ID) and the leading monogenic cause of autism spectrum disorder (ASD). Serotonergic neurotransmission has a key role in the modulation of neuronal activity during development, and therefore, it has been hypothesized to be involved in ASD and co-occurring conditions including FXS. As serotonin is involved in...
Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease is associated with autoimmune induced neuroinflammation. This case report describes an immunocompetent male with serologically positive neuropsychiatric Lyme disease who did not tolerate antimicrobial or psychotropic medications and whose symptoms...
Neurology BulletinDecember 24, 2022Vladimir D. Mendelevich, Veronika N. Konovalova, Galya M. Galiullina et al.
The article describes the case of Daria D., 23 years old, who has been using various drugs (LSD, marijuana, mephedrone) for a number of years and independently abandoned using drags with the transition to the use of microdoses of red fly agaric (Amanita Muskaria). Her mental and addictive status is analyzed. It is concluded that, despite the systematic use of drugs, there are no grounds for...
The COVID-19 pandemic exacerbated pre-existing high-levels of physician stress and burnout1. In order to help treat frontline colleagues who were diagnosed with acute stress disorder, we chose a non-psychedelic, ketamine micro-dose treatment strategy for symptom management.We provided care virtually, and all patients were prescribed sublingual ketamine once daily. Each patient was evaluated...
Since not only psilocybin (PSB) but also PSB-containing mushrooms are used for psychedelic therapy and microdosing, it is necessary to know their concentration variability in wild-grown mushrooms. This article aimed to determine the PSB, psilocin (PS), baeocystin (BA), norbaeocystin (NB), and aeruginascin (AE) concentrations in a large sample set of mushrooms belonging to genera previously...
Psilocybin is an emerging potential therapy for the treatment of psychiatric illnesses. Microdosing has been shown to result in an overall improvement in patients with anxiety, depression, obsessive-compulsive disorder, post-traumatic stress disorder, and substance abuse. This meta-analysis explores and compiles prior research to make further inferences regarding psilocybin and its use for the...
In an interesting and timely editorial, Borgland and Neyens provide a snap shot of preclinical research that could support the development of psyche delic drugs as part of a therapeutic regimen in individuals with obesity or eating disorders (EDs), including an orexia nervosa (AN) and binge eating disorder (BED).1 The role of the sero tonergic system in appetite was key in the development...
This phenomenological research explored the fast-growing societal trend in psilocybin microdosing, whereby a sub-perceptual amount of the psychedelic is consumed regularly. Anecdotal reports of microdosing have suggested that individuals can experience the relief of depressive symptoms, greater creativity and focus, deeper connections, and improvements in several mental health issues. Research...
Abstract Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psilocybin induces long-lasting effects on behavior, likely due to its profound ability to alter consciousness and augment neural connectivity and plasticity. Impaired synaptic plasticity in obesity contributes to ‘addictive-like’ behaviors, including...
While LSD may have had a harsh reputation in decades previous, current research has been investigating its potential as a therapeutic modality. It has been shown that full doses of LSD are capable of providing therapeutic effects however, the concept of "microdosing", or the repeated use of very low doses has become increasingly popular. Yet, the literature does not provide consistent results...